The strong correlation between these pathways and breast cancer patient survival, treatment relapse, and immune inhibitory mediators such as PD-1 and LAG3 highlights their potential as therapeutic targets for preventing and treating metastatic diseases. Here, LAG3 is linked to breast carcinoma.